论文标题
冠状病毒SARS-COV-2：亚基因组mRNA转录，3CLPRO和PL2PRO蛋白酶裂解位点以及蛋白质合成的分析
Coronavirus SARS-CoV-2: Analysis of subgenomic mRNA transcription, 3CLpro and PL2pro protease cleavage sites and protein synthesis
论文作者
论文摘要
Coronaviruses have recently caused world-wide severe outbreaks: SARS (Severe Acute Respiratory Syndrome) in 2002 and MERS (Middle-East Respiratory Syndrome) in 2012. At the end of 2019, a new coronavirus outbreak appeared in Wuhan (China) seafood market as first focus of infection, becoming a pandemics in 2020, spreading mainly into Europe and Asia.尽管病毒家族是众所周知的，但该特定病毒呈现出很大的差异，因为较高的传播率，是诊断方法，治疗和疫苗的挑战。冠状病毒（C ++）。Pro是一种C ++应用，可模拟冠状病毒复制周期。该软件已在短时间内确定了病毒类型，并提供了病毒蛋白的FASTA文件，即mRNA序列和二级结构的列表。此外，该软件在2019年NCOV病毒基因组中确定了与SARS相比，与MER相比，该软件的结构，非结构性和附属蛋白列表，因为该病毒类型的几种融合蛋白特征。这些结果是开发诊断方法，新疫苗或抗病毒药物的第一步，可以避免在任何阶段避免病毒复制：融合抑制剂，RDRP抑制剂和PL2PRO/3CLPRO蛋白酶抑制剂。
Coronaviruses have recently caused world-wide severe outbreaks: SARS (Severe Acute Respiratory Syndrome) in 2002 and MERS (Middle-East Respiratory Syndrome) in 2012. At the end of 2019, a new coronavirus outbreak appeared in Wuhan (China) seafood market as first focus of infection, becoming a pandemics in 2020, spreading mainly into Europe and Asia. Although the virus family is well-known, this specific virus presents considerable differences, as higher transmission rates, being a challenge for diagnostic methods, treatments and vaccines. Coronavirus(C++).pro is a C++ application which simulates Coronavirus replication cycle. This software has identified virus type in short times and provided FASTA files of virus proteins, a list of mRNA sequences and secondary structures. Furthermore, the software has identified a list of structural, non-structural and accessory proteins in 2019-nCoV virus genome more similar to SARS than to MERS, as several fusion proteins characteristics of this virus type. These results are useful as a first step in order to develop diagnostic methods, new vaccines or antiviral drugs, which could avoid virus replication in any stage: fusion inhibitors, RdRp inhibitors and PL2pro/3CLpro protease inhibitors.
